The November supplement to the International Society of Nephrology's Journal, Kidney International, contains data presented at the International Symposium of Albuminuria in New York last May. The supplement titled "Albuminuria: Risk Marker and Target for Treatment" includes a broad array of research on the protein's predictive power as a risk marker and therapy target, its mechanism of action, and advances in how it is measured. The results illustrate that albuminuria is an independent risk marker for kidney and cardiovascular disease not only in at-risk patients such as diabetics but also in the general population. Initial data also suggests that albuminuria can serve as an independent therapy target, irrespective of cholesterol, blood pressure and other commonly used drug efficacy parameters.
